**Name of journal:** **World Journal of** **Gastroenterology**

**ESPS Manuscript NO: 21202**

**Manuscript Type:** **REVIEW**

**Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma**

Chiu AP *et al.*Transposon mouse models to elucidate genetic mechanisms of liver cancer

Amy P Chiu, Barbara R Tschida, Lilian H Lo, Branden S Moriarity, Dewi K Rowlands, David A Largaespada, Vincent W Keng

**Amy P Chiu**, **Lilian H Lo**, **Vincent W Keng**, Department of Applied Biology and Chemical Technology, the Hong Kong Polytechnic University, Kowloon, Hong Kong, China

**Barbara R Tschida**, **Branden S Moriarity**, **David A Largaespada**, Masonic Cancer Center, Department of Pediatrics, Center for Genome Engineering, University of Minnesota, Minneapolis, MI 55455, United States

**Dewi K Rowlands**, Laboratory Animal Services Centre, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong, China

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Supported by** Health Medical Research Fund No. 11122171, the Food and Health Bureau, and the Hong Kong SAR Government; and the Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong SAR (1-ZVAG, G-YBAY, G-UA94 and 1-ZE19). B.R.T. was supported by the NIH IMVTP grant T32 AI083196-04.

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:** **Vincent W Keng**, **PhD,** Department of Applied Biology and Chemical Technology, the Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China. vincent.keng@polyu.edu.hk

**Telephone**: +852-34008728

**Fax**: +852-23649932

**Received:** August 12, 2015

**Peer-review started:** August 13, 2015

**First decision:** September 11, 2015

**Revised:** September 18, 2015

**Accepted:** September 30, 2015

**Article in press:**

**Published online:**

**Abstract**

The major type of human liver cancer is hepatocellular carcinoma (HCC), and there are currently many risk factors that contribute to this deadly disease. The majority of HCC occurrences are associated with chronic hepatitis viral infection, and hepatitis B viral (HBV) infection is currently a major health problem in Eastern Asia. Elucidating the genetic mechanisms associated with HBV-induced HCC has been difficult due to the heterogeneity and genetic complexity associated with this disease. A repertoire of animal models has been broadly used to study the pathophysiology and to develop potential treatment regimens for HBV-associated HCC. The use of these animal models has provided valuable genetic information and has been an important contributor to uncovering the factors involved in liver malignant transformation, invasion and metastasis. Recently, transposon-based mouse models are becoming more widely used in liver cancer research to interrogate the genome by forward genetics and also used to validate genes rapidly in a reverse genetic manner. Importantly, these transposon-based rapid reverse genetic mouse models could become crucial in testing potential therapeutic agents before proceeding to clinical trials in human. Therefore, this review will cover the use of transposon-based mouse models to address the problems of liver cancer, especially HBV-associated HCC occurrences in Asia.

**Key words:** Hepatocellular carcinoma; Hepatitis B virus; Transposable elements; Sleeping Beauty; Forward and reverse genetic screens

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Hepatocellular carcinoma (HCC) is the major type of primary liver cancer and the risk factors that contribute to its formation are hepatitis viral infection, alcohol consumption, aflatoxin exposure, hemochromatosis, and tyrosinemia. *In vivo* forward and reverse genetic transposon models have been used to study the genetic mechanisms of HCC, including hepatitis B viral-induced HCC. These animal models provide valuable genetic information and are important contributor to uncovering the factors involved in liver malignant transformation, invasion and metastasis. They could also be used to test potential therapeutic agents before proceeding to clinical trials in humans.

Chiu AP, Tschida BR, Lo LH, Moriarity BS, Rowlands DK, Largaespada DA, Keng VW. Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma. *World J Gastroenterol* 2015; In press

**EPIDEMIOLOGY OF LIVER CANCER**

Liver cancer is the second most common cause of cancer related death worldwide, accounting for about 700000 deaths annually. Liver cancer has a poor prognosis, with less than 20% of advanced staged patients surviving for more than one year after initial detection[[1](#_ENREF_1)]. The major type of primary liver cancer is HCC, which accounts for 85% to 90% of total liver cancer cases[[2-4](#_ENREF_2)]. In 2012, 83% of 782000 new liver cancer cases worldwide occurred in Eastern Asian countries like Korea, China, Japan, as well as sub-Saharan, middle and Eastern Africa, with a high incidence rate of more than 20 per 100000 individuals. The incidence rate is particularly high in China, with 50% of the total new liver cancer cases diagnosed there[[2-6](#_ENREF_2)]. Middle Africa, Central America, North America, and Southern Europe have a moderately high incidence rate of about 10 to 20 per 100000 individuals, while a low incidence rate has been reported in South-Central Asia and Northern Europe with less than 5 liver cancer cases per 100000 individuals[[2-4](#_ENREF_2), [6](#_ENREF_6)].

Hepatocellular carcinoma (HCC) most often is diagnosed between the ages of 55 to 59 years old in China, and between 63 to 65 years old in Europe and North America[[3](#_ENREF_3),[4](#_ENREF_4)]. HCC is a gender-biased disease more commonly found in males than in females with the ratio of about 3:1 in high incidence rate countries. According to long historic studies, hormonal differences between males and females are one of the reasons for this gender bias phenomenon. Researchers have suggested the androgen receptor (AR), which can bind to testosterone and other male hormones and is more highly expressed in males than in females, can promote hepatitis B virus (HBV)-related HCC, while estrogen receptor 1 (ESR1) may work antagonistically[[7-10](#_ENREF_7)]. The activation of *Esr1* has been shown to dampen hepatitis B viral replication[[7](#_ENREF_7)], and estrogen can also protect female mice by repressing the expression ofinterleukin 6 (Il6)in Kupffer cells and resident macrophages in liver to prevent liver inflammation[[7](#_ENREF_7), [8](#_ENREF_8)].

HBV INFECTION

HBV infection is a major global health problem and, according to the World Health Organization, more than 300 million people suffer from chronic HBV infection and about 780000 people die every year due to acute or chronic consequences of the disease[[4](#_ENREF_4),[11](#_ENREF_11)]. Since 1970, chronic HBV infection has been shown to be closely related to the development of liver cirrhosis and HCC[[12](#_ENREF_12)]. The median survival rate for HBV-associated HCC is less than 16 months, and the five year survival rate is only 15% to 26%[[4](#_ENREF_4)].

In developing countries, chronic HBV infection accounts for most HCC cases with HBV mostly being transmitted from mother to infant and approximately 90% of infants born to chronic HBV-infected mothers eventually developing the disease[[4](#_ENREF_4)]. In contrast, HCV infection-associated cirrhosis and alcoholic cirrhosis account for the majority of HCC cases in developed countries that have access to HBV vaccination programs[[4](#_ENREF_4)]. In countries with these vaccination programs, HBV is usually transmitted sexually between adults and 90% of the virus can be spontaneously cleared by the infected host’s immune system[[4](#_ENREF_4)]. Although vaccines for HBV have been introduced to reduce the prevalence of HCC, HCC occurrence has not declined in the last two decades due to high chronic HBV infection prevalence and prolonged HCC development latency[[4](#_ENREF_4)].

HBV GENOTYPES

As of 2011, 10 HBV genotypes (A to J) have been identified and classified by their infectious geographical distribution. Genotype A is widely distributed in South and West Africa and in Western and Northern parts of Europe. Genotypes B and C are commonly found in East and Southeast Asia, including China, while genotype D is distributed mainly in the Mediterranean area[[4](#_ENREF_4)]. Any genomic variations of HBV, such as genotypes, sub-genotypes, and HBV gene mutations can further contribute to the development of liver cirrhosis and HCC in patients with different HBV replication and hepatitis B surface antigen (HBsAg) status[[4](#_ENREF_4),[5](#_ENREF_5)]. Prolonged expression of HBV correlates to the development of HCC, likely due to the presence of its viral proteins such as the X gene (HBx) and/or large envelope proteins. These viral proteins can activate cellular cancer-related genes, induce oxidative stress, and promote genetic instability that further contributes to hepatocyte transformation[[13](#_ENREF_13)]. HCC tumorigenesis is also influenced by the patient’s viral status such as the HBV genotype, hepatitis B e antigen (HBeAg) serostatus and mutational status of the HBV genome[[4](#_ENREF_4)]. There is a higher occurrence of HBV genotypes B and C, and an increasing prevalence of HBsAg serostatus in China. Genotype C seems to have a stronger causative effect than genotype B on HCC development[[4](#_ENREF_4),[14](#_ENREF_14)]. Therefore, it is hypothesized that pathogenicity may be associated with the HBV genotype.

HBV GENOME

HBV belongs to the *hepadnaviridae* family of enveloped viruses and has an incomplete double-stranded DNA genome of 3.2 kilobases (kb) (Figure 1). The double-stranded HBV genome consists of four open reading frames (ORFs): PreS1/PreS2/S ORF encodes the three large-, middle-, and small HBsAg proteins; PreC/C ORF encodes the hepatitis core protein (HBcAg) and HBeAg, a soluble small molecular weight protein produced by the viral core protein gene (PreC/C region) with an alternative start codon and post-translational modification[[15](#_ENREF_15)]; POL ORF encodes the four viral polymerases that consists of the RNase H, viral DNA polymerase/reverse transcriptase, spacer, and terminal protein; X ORF encodes the multi-functional non-structural hepatitis X protein, which can function as a transcriptional transactivator and promote HBV replication (Figure1)[[4](#_ENREF_4),[16](#_ENREF_16),[17](#_ENREF_17)]. The effects of HBV surface proteins and HBx protein on tumorigenesis have been widely studied but their molecular mechanisms remain elusive.

***HBV PreS1/S2/S ORF***

Three main HBsAg proteins are synthesized by three individual promoters and start sites. The PreS1 promoter drives the transcription of PreS1/S2/S ORF to form the large protein (L); the PreS2/S promoter drives the transcription of PreS2/S ORF to form the middle protein (M); while transcription of S ORF only forms the small protein (S) (Figure1). All these HBsAg proteins have the same carboxyl (C)-terminus but different amino (N)-terminal extensions: the S protein forms the HBsAg with only 226 amino acids (aa), the M protein has an additional 55 aa N-terminal extension, while the L protein has a further N-terminal extension of 108, 118, or 119 aa, depending on the HBV genotype[[5](#_ENREF_5),[18](#_ENREF_18),[19](#_ENREF_19)]. A central major hydrophilic region formed by residues 103-173 is exposed to the surface of the viral particles[[5](#_ENREF_5)]. HBsAg is the main target for viral neutralization by either natural or vaccine-induced anti-HBs antibodies[[5](#_ENREF_5),[18](#_ENREF_18)]. The PreS1 ORF plays a key role in HBV infectivity through its role in nucleocapsid binding during virus envelopment and in receptor binding during hepatocyte infection[[18](#_ENREF_18),[20](#_ENREF_20),[21](#_ENREF_21)].

The PreS1 and PreS2 ORFs of HBV can initiate host immune responses as both contain several epitopes for B cell and T cell recognition. Therefore, mutations in these two ORFs can lead to a host immune response defect, resulting in chronic HBV infection[[4](#_ENREF_4),[22](#_ENREF_22)]. Numerous clinical studies have shown deletions in the PreS1 3’-end and PreS2 5’-end are frequently found in chronic HBV infected patients[[22-25](#_ENREF_22)]. Additional types of mutations that can occur in the PreS ORFs include deletions, insertions and substitutions. Importantly, presence of these mutations has been found to correlate closely with HCC tumorigenesis[[4](#_ENREF_4),[22](#_ENREF_22)]. Deletion mutations that commonly occur can be classified into four categories: PreS1 start codon deletion, internal deletion of PreS1, PreS2 start codon deletion, and internal deletion of PreS2[[23](#_ENREF_23)]. Generally, the PreS deletion sites are commonly located at the PreS1 and PreS2 region of the HBV genome (Figure2)[[23](#_ENREF_23), [25](#_ENREF_25)]. In addition, insertions and substitutions have also been reported in chronic HBV infected patient samples[[25](#_ENREF_25)]. Most neutralizing antibodies target the immunodominant “a” determinant region that is formed by residues 124-147, whereas glycine to arginine substitution at position 145 (G145R) in the “a” determinant region of the S ORF occurs commonly in immune evasive mutant variants[[5](#_ENREF_5),[18](#_ENREF_18),[26](#_ENREF_26)]. Other mutations occurring outside the “a” determinant region but within the S ORF, such as the P120S/T mutation, can also exhibit immune evasive effects. These mutant variants are associated with the clinical detection of HBV DNA in patient serum despite the absence of detectable HBsAg[[5](#_ENREF_5)]. Substitution mutations can result in premature termination during gene transcription, resulting in the production of truncated HBsAg. These truncated HBsAgs can accumulate in the hepatic endoplasmic reticulum (ER), increase oxidative stress of the cell and eventually accelerate liver cell damage[[23](#_ENREF_23),[25](#_ENREF_25)].

PreS deletion mutants can induce liver tumor formation by (1) altering the PreS1 mRNA to PreS2/S mRNA ratio; (2) inducing ER oxidative stress; and (3) allowing escape from host immune system surveillance, whereas the 3’-end deletion in the PreS2 domain and removal of the CCAAT element in the S promoter domain is also thought to reduce transcription of the 2.1 kb PreS2/S mRNA[[23](#_ENREF_23)]. The CCAAT element increases the transcription of PreS2/S ORF and decrease transcription of PreS1 ORF, thus the deletion of this CCAAT element would alter the PreS1 mRNA to PreS2/S mRNA ratio. This decrease in transcription of PreS2/S ORF therefore reduces synthesis of S protein and eliminates synthesis of M protein. Normally, L protein can only be secreted as sub-viral particles or mature virions by forming a complex with the M and S protein. Insufficient amounts of both M and S protein would therefore result in the accumulation of L protein in hepatic ER that induces oxidative stress by generating high levels of reactive oxygen species (ROSs) that can cause oxidative DNA damage, induce genetic mutations, and ultimately lead to HCC development[[23](#_ENREF_23), [27](#_ENREF_27)].

PreS deletion mutants have also been implicated in the prevention of apoptosis in hepatocytes by activating the nuclear factor of kappa light polypeptide gene enhancer in B-cell 1 (NFKB1) and v-akt murine thymoma viral oncogene homolog 1 (AKT1)/mechanistic target of rapamycin (serine/threonine kinase) (MTOR) signaling pathways by upregulating the prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2) and vascular endothelial growth factor (VEGF) protein production, respectively[[23](#_ENREF_23),[27](#_ENREF_27)]. In addition, hepatocytes transfected with the PreS2 deletion mutant can also evade the host immune system surveillance due to its altered epitopes sites (b10, t5, t6) for B-cell and T-cell recognition and/or reduction in binding affinity of the viral proteins to major histocompatibility complex I molecule[[23](#_ENREF_23),[27](#_ENREF_27),[28](#_ENREF_28)].

***X ORF***

The X ORF encodes the multifunctional HBx protein consisting of 154 aa[[16](#_ENREF_16),[29](#_ENREF_29)]. The genetic mechanism(s) by which HBx induces and/or contributes to HCC development is still not well understood. However, it has been shown that HBx protein plays a critical role in hepatocyte transformation in three ways: (1) changing the epigenetic status; (2) inducing genomic instability; and (3) modulating signaling pathways[[13](#_ENREF_13),[30](#_ENREF_30)].

HBx can change the epigenetic status of hepatocytes, leading to the inactivation of host tumor suppressor genes and/or activation of host oncogenes through induction of various DNA methyltransferases[[30](#_ENREF_30),[31](#_ENREF_31)]. HBx is able to bind to histone acetyltransferase complex and CREB binding protein, promoting transactivation reactions and leading to histone hyperacetylation[[13](#_ENREF_13),[29-31](#_ENREF_29)]. In addition, HBx can promote the production of H3-K4-specific methyltransferase by upregulating *SET and MYND domain containing 3* gene expression that increases H3 lysine K4 methylation[[31](#_ENREF_31)]. HBx can recruit the binding of DNA (cytosine-5-)-methyltransferase 1 and 3A (DNMT1 and DNMT3A) onto tumor suppressor genes and alter their methylation status and expression level. Conversely, HBx can also inhibit the binding of DNMT3A to promoters, releasing the hypomethylated status of tumor-promoting genes and inducing their expression[[31](#_ENREF_31)]. *DNMT3A* has been shown to be associated with hepatocarcinogenesis, as a higher expression level of *DNMT3A* has been reported in HCC patients[[30](#_ENREF_30)]. The transcriptional transactivation activity of HBx includes the upregulation of *DNMT1* and *DNMT3A*, which induces cytosine-guanine dinucleotide (CpG) island methylation at the carbon-5 position of cytosine. This *DNMT1* and *DNMT3A* upregulation prevents binding of transcription factors and RNA polymerase II complexes to tumor suppressor genes, such as *cyclin-dependent kinase inhibitor 2A* (*CDKN2A*) and *cadherin 1, type 1, E-cadherin (epithelial)* (*CDH1*), resulting in their inactivation[[30](#_ENREF_30), [31](#_ENREF_31)]. In addition, HBx can also promote binding of histone deacetylases to tumor suppressor genes to suppress their transcription[[31](#_ENREF_31)].

In addition to inducing epigenetic changes, HBx is also believed to enhance genomic instability. HBx has been associated with the inactivation of various tumor suppressor genes such as *tumor protein p53* (*TP53*)*, retinoblastoma 1* (*RB1*)*,* and *axin 1* (*AXIN1*). HBx inhibits major DNA repair pathways by the interaction with tumor suppressor proteins in these pathways, leading to enhanced genomic instability from the accumulation of mutations and deletions[[32-35](#_ENREF_32)]. HBx can also increase angiogenesis by upregulating *VEGF* transcription and stabilizing *hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)* (*HIF1A*)[[29](#_ENREF_29)]. Recently, several *in vivo* research studies have demonstrated HBx overexpression upregulates *catenin (cadherin-associated protein), beta 1, 88kDA* (*CTNNB1*) in the important canonical wingless-type MMTV integration site family (WNT)/CTNNB1 signaling pathway implicated in hepatocarcinogenesis[[29](#_ENREF_29),[36](#_ENREF_36),[37](#_ENREF_37)].

Four common mutation sites have been identified in the HBx ORF: nucleotide position T1753C (I127T amino acid substitution), A1762T (K130M amino acid substitution), G1764A (V131I amino acid substitution) and T1768A (F132Y amino acid substitution)[[38](#_ENREF_38)]. The combinatory effects of these mutations have been studied *in vitro* using the human liver cell line (CCL13) where both K130M and V131I mutations had the potential to induce cell proliferation (Figure 3)[[38](#_ENREF_38),[39](#_ENREF_39)].

Another form of HBx mutation is the C-terminal truncation (Figure 3). The role of HBx in HBV replication has been carefully studied in HepG2 and Huh7 cell lines[[16](#_ENREF_16),[40](#_ENREF_40),[41](#_ENREF_41)]. HBx contains two active domains: a negative regulatory domain in the N-terminus and a transactivation or co-activation domain in the C-terminus that can transactivate viral and cellular promoters[[16](#_ENREF_16)]. *In vitro* experiments have shown 52 to 65 aa and 88 to 154 aa in the C-terminus of HBx are necessary for its transactivation activity, cell cycle regulation, and HBx stability[[16](#_ENREF_16),[40](#_ENREF_40),[41](#_ENREF_41)]. Upon integration of the HBV genome into the host genome, the 3’-end of HBx is often deleted and produces the C-terminal truncated form of HBx[[42](#_ENREF_42),[43](#_ENREF_43)]. Clinically, C-terminal truncated HBx has been commonly detected in tumors of HCC patients[[42](#_ENREF_42),[44](#_ENREF_44),[45](#_ENREF_45)]. Importantly, this C-terminal truncated HBx has been shown to promote tumor cell proliferation and metastasis compared to full-length HBx[[42](#_ENREF_42),[44](#_ENREF_44),[46](#_ENREF_46)]. Furthermore, C-terminal truncated HBx has shown to abrogate the growth suppression and apoptotic effect of full-length HBx in cell lines[[42-44](#_ENREF_42),[46](#_ENREF_46)]. However, the genetic mechanism(s) of how this C-terminal truncated HBx affects the tumorigenicity of HBV still remains unclear.

**MECHANISMS OF HBV-INDUCED HCC**

Increasing evidence has shown HBV infection plays an important role in the development of HCC. Two major mechanisms involved in HBV-associated HCC pathogenesis are: (1) integration of the viral genome into the host chromosome; and (2) the expression of the *trans*-activating factors derived from the HBV genome[[13](#_ENREF_13),[15](#_ENREF_15),[29](#_ENREF_29),[47](#_ENREF_47)]. Although, during the normal lifecycle of HBV, the viral genome present in the host nucleus is a covalently closed circular DNA (cccDNA) (Figure 4), about 80% of the HBV-related HCC are found to have the HBV genome integrated into the host chromosome[[13](#_ENREF_13)]. The integration of the viral genome into the host DNA can disrupt and/or promote cellular gene expression involved with cell growth and differentiation[[47](#_ENREF_47)]. In addition, the expression of *trans*-activating factors derived from the expression of viral DNA may influence intracellular signaling pathways and affect host gene expression[[47](#_ENREF_47)]. Elevated levels of truncated PreS2/S, HBx, and hepatitis B spliced protein have been found in infected tumor tissue[[47](#_ENREF_47)]. HBx has been shown to play a role in pleiotropic functions and to be involved in the malignant transformation of chronically-infected liver cells[[47](#_ENREF_47)]. HBx can induce cell proliferation, oxidative stress, and host DNA damage and ultimately contribute to HCC tumorigenesis[[13](#_ENREF_13),[15](#_ENREF_15)]. Recent studies have found HBx can activate *CTNNB1* expression and inactivate *TP53*[[15](#_ENREF_15),[37](#_ENREF_37)]. The activation of the WNT/CTNNB1 signaling pathway is vital in the genetic evolution of HCC[[48](#_ENREF_48)]. Elevated levels of truncated surface proteins have also been found in HCC patients chronically infected with HBV.

MOST FREQUENTLY MUTATED GENES IN HBV-ASSOCIATED HCC

The relationship of somatic mutation of *telomerase reverse transcriptase* (*TERT*) and different types of cancer has been highly reported. Recently, the relationship between *TERT* and HCC has becoming more obvious: the *TERT* promoter was shown to be mutated in 54% of 469 HCC cases and in 37% of HBV-positive cases, where the mutation site was most likely located 124 bp upstream the *TERT* start codon[[49](#_ENREF_49)]. Moreover, there was 22% focal amplification rate of *TERT* in HBV-positive samples[[49](#_ENREF_49)]. The combined *TERT* promoter mutation and focal amplification causes higher *TERT* expression in HCC[[49](#_ENREF_49)]. Apart from *TERT*, recent exome sequencing of HCC tumors have identified at least 30 significant putative HCC driver genes involved in 11 signaling pathways: WNT/CTNNB1, mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/AKT/MTOR, TERT, TP53/cell cycle, hepatic differentiation, epigenetic regulation, chromatin remodeling, oxidative stress, IL6/Janus kinase (JAK)-STAT3 and TGFB[[49](#_ENREF_49),[50](#_ENREF_50)]. Amongst these putative driver genes, somatic mutations and copy number changes of *CTNNB1*, *TP53*, *AT rich interactive domain 1A* (*SWI-like*) (*ARID1A*) and *AXIN1* were significantly altered in 10% of HCC patient samples[[49](#_ENREF_49),[50](#_ENREF_50)]. *TP53* mutations are common in most cancer types, so it is not surprising that similar *TP53* mutation frequencies in HBV-related HCC have been widely reported by numerous studies[[37](#_ENREF_37),[49-51](#_ENREF_49)]. Furthermore, 16% of the *TP53* mutations identified in genotype B HBV-related HCC were found at the R249S site, usually associated with aflatoxin-induced HCC[[51-53](#_ENREF_51)].

**NEED FOR MOUSE MODELS OF HBV-INDUCED HCC**

Although a few mechanisms by which HBV may promote HCC have been identified, they need to be better characterized in order for the understanding of the genetic mechanisms of HBV-induced HCC to be complete. While it is promising that several common mutations driving HCC in context of HBV infection have been identified, there are many more mutations present in HBV-associated liver tumors that may be important in driving tumor phenotypes[[54](#_ENREF_54),[55](#_ENREF_55)]. Of the many mutations found in HBV-associated liver tumors, the drivers need to be identified and characterized. Mouse models may provide an effective tool for this.

**FORWARD GENETIC SCREENS FOR DRIVERS OF HCC USING TRANSPOSON INSERTIONAL MUTAGENESIS**

The discovery of inducing lymphoma and mammary cancer formation in mouse models through retroviral insertional mutagenesis by murine leukemia virus or mouse mammary tumor virus has accelerated the speed of identifying driver mutations within these tumor types[[56](#_ENREF_56)]. However, the application of retroviral insertional mutagenesis has been limited to these specific cancers. Therefore, it may be more valuable to apply an insertional mutagenesis method that is applicable in oncogenomic studies for more human cancer types.

Transposons are such genetic tools that can be used for insertional mutagenesis in multiple tissues in most mammalian species. One transposon that has been successfully used for both forward and reverse genetic interogation of the oncogenome is *Sleeping Beauty* (*SB*)[[57](#_ENREF_57)]. The synthetic *SB* transposon belongs to the *Tc1*/mariner family of class II transposable elements[[57](#_ENREF_57)]. The *SB* transposon system consists of two components: a transposon and transposase. The transposon can be any DNA sequence flanked by inverted repeat/direct terminal repeat (IR/DR) sequences. The transposase binds to the IR/DR sequences and mediates the excision and reintegration of the transposon from one locus to another in a “cut-and-paste” manner[[57](#_ENREF_57)]. The target integration site for *SB* is a TA-dinucleotide pair and, with approximately 300 million sites in the mouse genome, allows for ample sites for insertional mutagenesis[[58](#_ENREF_58),[59](#_ENREF_59)]. The process of transposition or mobilization is relatively random, although “local hopping” may occur[[60-62](#_ENREF_60)].

Tissue-specific mutagenesis with the *SB* transposon system has been made possible with the use of a conditional system, which has allowed for transposon insertional mutagenesis in mice to recapitulate several important human cancers for genetic analyses, including liver, gastrointestinal tract, skin, blood, bone, prostate and nervous system[[63-75](#_ENREF_63)]. In this review we focus on the use of the conditional *SB* insertional mutagenesis system in several forward genetic screens for HCC candidate genes[[63-67](#_ENREF_63),[75](#_ENREF_75)]. Briefly, mice carrying the following transgenes were generated for each of these forward genetic screens for liver cancer genes: conditional *SB* transposase transgene, mutagenic transposon, hepatocyte-specific *Cre* recombinase and predisposed genetic background[[63](#_ENREF_63),[66](#_ENREF_66)]. The *SB* transposase (*SB11*) carrying a floxed-stop (lsl) cassette knocked into the mouse endogenous *Rosa26* locus can only be activated by a tissue-specific *Cre* recombinase, allowing for expression and mobilization of transposons exclusively in hepatocytes[[64](#_ENREF_64)]. The mutagenic transposon, T2/Onc, consists of splice acceptor/polyadenylation (SA/pA) sequences in both orientations and a *murine stem cell virus* (*MSCV*) long terminal repeat (LTR) containing promoter/enhancer elements followed by a splice donor that can facilitate splicing of transcripts initiated in the *MSCV* into downstream endogenous exons[[68](#_ENREF_68),[74](#_ENREF_74)]. The mutagenic transposon was designed to allow for both gain-of-function and loss-of-function mutational activity when integrated into the host genome. When the mutagenic transposon is inserted in a tumor suppressor gene, normal splicing event will be disrupted by the SA/pA elements. Alternatively, misexpression of a proto-oncogene by the *MSCV* LTR element will occur if the mutagenic transposon is inserted within or near these genes[[68](#_ENREF_68),[74](#_ENREF_74)].

Since *TP53* is commonly mutated in HBV-related HCC[[51-53](#_ENREF_51)], and HBx has been found to inactivate *TP53*[[76-78](#_ENREF_76)], studying the genetic drivers of HCC in context of *transformation related protein 53* (*Trp53*) mutation in a mouse model may shed light on the genetic alterations required for HBV-induced HCC development. Using the conditional transposon system together with a conditional dominant negative *Trp53* transgene as a predisposed genetic background, 19 highly significant common insertional sites (CISs) for HCC-associated genes were identified[[66](#_ENREF_66)]. The three most significant signaling/disease functional annotations were identified through analyzing CIS genes by Ingenuity Pathway Analysis (IPA): post-translational modification, cancer, and tumor morphology. *Epidermal growth factor receptor* (*EGFR*), *HIF1A*, *mitogen-activated protein kinase kinase 4* (*MAP2K4*), *MET proto-oncogene, receptor tyrosine kinase* (*MET*), *p21 protein (Cdc42/Rac)-activated kinase 4* (*PAK4*), *vaccinia related kinase 2* (*VRK2*), *transient receptor potential cation channel, subfamily M, member 7* (*TRPM7*) and *TAO kinase 3* (*TAOK3*) have been shown to be involved in tumor formation and apoptsis[[66](#_ENREF_66)]. Nuclear factor I/B (NFIB) and HIF1A network pathways were also identified by IPA and have been implicated in the transduction of phosphorylation-signaling cascades from *EGFR*[[66](#_ENREF_66)]. *PAK4*, *NFIB*, *TAOK3*, *EGFR*, *MET*, *MAP2K4*, *HIF1A*, *ubiquitin-conjugating enzyme E2H* (*UBE2H*), and *QKI, KH domain containing, RNA binding* (*QKI*) were found to potentially interact with *tumor necrosis factor* (*TNF*), inducing tyrosine phosphorylation and internalization of *EGFR* that might activate the nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFKB1) pathway that regulates apoptosis during liver tumor formation (Table 1)[[66](#_ENREF_66)]. In addition, a high frequency of mutagenic transposon insertions were found in intron 24 of the *Egfr* gene. This insertion results in the production of C-terminal truncated Egfr protein, which transphosphorylates the tyrosine sites of v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (Erbb2) and activate other signaling pathways that contribute to HCC tumorigenesis[[66](#_ENREF_66)]. In addition, this study also revealed 3 strong candidate genes (*UBE2H, QKI, MAP2K4*) associated with HCC. *QKI* and *MAP2K4* have a significant decrease in DNA copy number and mRNA level and a high proportion of deletion mutations in human HCC samples, suggesting that both are putative HCC tumor-suppressor genes[[66](#_ENREF_66),[79](#_ENREF_79),[80](#_ENREF_80)]. The significant increase in DNA copy number, mRNA level, and high mRNA up-regulation rate of *UBE2H* indicate that it is a putative HCC tumor-promoting gene[[66](#_ENREF_66),[79](#_ENREF_79),[80](#_ENREF_80)].

Incorporating the *SB* transposon system with a common dysregulated human malignancy gene, *v-myc avian myelocytomatosis viral oncogene homolog* (*MYC*), 18 CISs in early-developing liver tumors were identified[[67](#_ENREF_67)]. It was shown that *zinc finger protein, X-linked* (*Zfx*) plays a tumor suppressor role in liver tumorigenesis, while *nuclear receptor coactivator 2* (*Ncoa2*)and *dystrobrevin, beta* (*Dtnb*)function as putative tumor-suppressors[[67](#_ENREF_67)]. In addition, expression of *NCOA2* and its target gene *glucose-6-phosphatase, catalytic subunit* (*G6PC*) were significantly reduced in human tumor samples and this reduction was strongly associated with the low survival rates of HCC patients[[67](#_ENREF_67)].

Using the *SB* transposon insertional mutagenesis mouse model incorporating the HBsAg transgene in a forward genetic screen, over 2000 candidate drivers of HBV-associated HCC were identified[[63](#_ENREF_63)]. In this study, 21 genes with highly significant sequencing read counts and frequencies of occurrence were identified to be candidate HCC genes[[63](#_ENREF_63)]. Of these candidate genes, 4 genes were identified as putative tumor suppressor genes: *adenosine kinase* (*Adk*)*, dihydropyrimidine dehydrogenase* (*Dpyd*), *lysine (K)-specific methyltransferase 2E* (*Kmt2e*) and *nuclear factor I/A* (*Nfia*); 6 genes were found to have tumor suppressing effects in HCC: *Arid1a*, *Gsk3b*, *IG motif containing GTPase activating protein 2* (*Iqgap2*), *membrane associated guanylate kinase, WW and PDZ domain containing 1* (*Magi1*), *Pten* and *salvador homolog 1* (*Sav1*); 2 genes were found to be involved in hepatocyte differentiation and maturation: *zinc finger and BTB domain containing 20* (*Zbtb20)* and *ankyrin repeat domain 17* (*Ankrd17*); 6 genes were found to regulate hepatic metabolism: *phosphatase and tensin homolog* (*Pten*)*, glycogen synthase kinase 3 beta* (*Gsk3b*)*, growth hormone receptor* (*Ghr*)*, Adk, Zbtb20,* and *Dpyd*; and 7 genes were found to be associated with HCC transcription modulation: *Kmt2e, SET domain containing 2* (*Setd2*)*, WW domain containing adaptor with coiled-coil* (*Wac*)*, Arid1a, Nfia, staphylococcal nuclease and tudor domain containing 1* (*Snd1*), and *Zbtb20*[[63](#_ENREF_63)]. Through CIS gene annotation enrichment analysis, it was found that HBsAg CIS genes drive HCC through conserved cancer signaling pathways, including Wnt/Ctnnb1, Trp53, Pi3k-Akt-Mtor, Mapk, Hippo, transforming growth factor beta (Tgfb)-bone morphogenic protein (Bmp) and Il6-signal transducer and activator of transcription 3 (Stat3) (Table 1)[[63](#_ENREF_63)]. Moreover, it was revealed that the majority of the HCC CIS genes were involved in cellular metabolic processes[[63](#_ENREF_63)]. It was suggested that disruption of glycolytic and glutaminolytic pathways provided bioenergetics, biosynthesis and redox regulation benefits for tumor cell division, thus inhibiting glycolysis and/or glutaminolysis might impede liver tumor formation or progression[[63](#_ENREF_63)]. Genetic alterations, copy number changes, and expression levels of the human orthologs of CIS genes from three separate *SB* transposon forward genetic screens with different genetic backgrounds were analyzed in TCGA database and presented as a word cloud (Wordle) to view the degree of genetic alteration reported in clinical samples (Figure 5)[[63](#_ENREF_63), [65](#_ENREF_65), [67](#_ENREF_67)].

REVERSE GENETIC VALIDATION USING RAPID TRANSPOSON-BASED MOUSE MODELS

The *SB* transposon system can also be used in a reverse genetic manner to introduce tumorigenic genes into mouse hepatocytes for stable expression when delivered on transposon plasmids to the mouse liver by hydrodynamic tail vein injection[[37](#_ENREF_37),[59](#_ENREF_59),[65](#_ENREF_65),[66](#_ENREF_66),[75](#_ENREF_75),[81](#_ENREF_81)]. Hydrodynamic injection is a rapid and high-volume infusion of naked plasmid DNA into the tail vein. It is an effective method for *in vivo* gene delivery, in which about 40% of the hepatocytes in a test animal take up the transgene and express > 95% of the transgene after hydrodynamic injection[[59](#_ENREF_59)]. The mechanism of DNA uptake is still poorly understood, but it is suggested that the injected high-volume of DNA solution enters the inferior vena cava and causes over-stretching of myocardial fibers, induces cardiac congestion, resulting in delivery of injected solution into liver[[82](#_ENREF_82)]. In addition to its use in mice, this method can also be used to transfer naked plasmid DNA into porcine and rabbit livers and into muscles of larger animals[[59](#_ENREF_59),[82](#_ENREF_82)]. The sporadic expression of target genes mimics a more realistic situation in human liver cancer than other conventional conditional transgenic models.

A powerful method to test genes’ oncogenic roles in the liver employs this gene delivery system to deliver tumorigenic genes to the livers of *fumarylacetoacetate hydrolase* (*Fah*)-deficient/*Rosa26*-SB11 (*Fah-/-*/*SB+/-*) transgenic mice[[37](#_ENREF_37),[59](#_ENREF_59),[65](#_ENREF_65),[66](#_ENREF_66),[75](#_ENREF_75),[81](#_ENREF_81),[83](#_ENREF_83)]. This is a selective model allowing for rapid generation of mice in which nearly all hepatocytes express the delivered transgenes. *Fah*-deficient mice have a defect in the last step of the tyrosine catabolic pathway in which fumarylacetoacetate is hydrolyzed to acetoacetate and fumarate, similar to the human hereditary tyrosinemia type I disease[[84](#_ENREF_84)]. These mice must be maintained on nitisinone in the drinking water, which blocks this pathway upstream of fumarylacetoacetate production[[84](#_ENREF_84)]. Oncogenes to be tested are co-delivered on transposon plasmids with a *Fah* rescue cDNA, and nitisinone is removed after gene delivery. Nitisinone removal causes *Fah*-deficient hepatocytes to die, and the liver is regenerated by hepatocytes that stably express the delivered transgenes[[37](#_ENREF_37),[59](#_ENREF_59),[65](#_ENREF_65),[66](#_ENREF_66),[75](#_ENREF_75),[81](#_ENREF_81)]. This system has been used in a reverse genetic manner to introduce tumorigenic genes into the livers of *Fah-/-*/*SB+/-* transgenic mice by hydrodynamic tail vein injection for validation in several studies[[37](#_ENREF_37),[59](#_ENREF_59),[65](#_ENREF_65),[66](#_ENREF_66),[75](#_ENREF_75),[81](#_ENREF_81)].

*SB*-mediated gene delivery to *Fah-/-*/*SB+/-* transgenic mice by hydrodynamic tail vein injection has been used to study the role of *HBx* in promoting liver cancer[[37](#_ENREF_37)]. The study showed that a transposon vector containing the HBx gene and *Fah* cDNA was delivered with and without a transposon vector containing a short hairpin RNA directed against *Trp53* (shp53). HBx expression activated *Ctnnb1* expression, and HBx cooperated with shp53 to induce the formation of hyperplastic nodules. This study showed this method could be used to model liver cancer driven by HBV gene components and elucidate mechanisms by which they may promote cancer.

We are currently attempting to use this method to test the roles other HBV genes in driving liver cancer. Using the Gateway cloning system (Life Technologies), we have constructed transposon plasmids with various individual HBV gene components for tumorigenic analyses in livers of *Fah-/-*/*SB+/-* transgenic mice. Hepatocytes that are transgenic for both the *Fah* cDNA and HBV gene-of-interest will repopulate the *Fah*-deficient liver, mimicking disease progression. Preliminary unpublished studies have yielded promising development of tumors in certain HBV gene-injected mice compared with empty vector controls(Figure 6). These tumors will be further interrogated for their genetic information such as gene expression profiles and/or pathway analyses. It is envisaged that genetic information from such *in vivo* studies will provide insight into underlying genetic mechanisms of HBV-induced HCC.

*SB*-mediated gene delivery for reverse genetic studies in mice, in addition to its use in studying the oncogenic roles of viral genes, could be used to rapidly validate candidate genetic drivers of HBV-associated HCC discovered in forward genetic screens as described above or genes found to be commonly altered in human HBV-associated HCC. Candidate drivers could be tested in context of expression of HBV viral genes using this system. In addition, hydrodynamic delivery of plasmid DNA expressing HBV genome components has been used to model HBV infection in mice[[85-87](#_ENREF_85)]. Candidate HBV-associated HCC drivers could be added on separate plasmids to test their roles in HCC in context of a model of HBV infection *in vivo*.

DISCUSSION

Based on the limited existing treatments and the poor prognosis of HCC, continuous efforts should be put into uncovering the mechanisms of drug resistance and tumor progression and on the development of biomarkers for more sensitive diagnosis and as molecular targets for new therapies. HBV infection is a major risk factor for HCC development, understanding its interactions with cancer-driving signaling pathways and its contributions to tumor initiation, promotion and progression will be critical for developing biomarkers for diagnosis and therapy.

In addition, recent exome sequencing of HCC patient samples have identified multiple cellular signaling pathways, including WNT/CTNNB1, MAPK, PI3K/AKT/MTOR, TERT, TP53/cell cycle, hepatic differentiation, epigenetic regulation, chromatin remodeling, oxidative stress, IL6/JAK-STAT3 and TGFB[[49](#_ENREF_49),[50](#_ENREF_50)]. In addition, numerous significant HCC driver genes, such as *TERT, TP53, CTNNB1, AXIN1* and *ARID1A* have also been identified[[49](#_ENREF_49),[50](#_ENREF_50)]. Additionally, *TP53* mutation was frequently found in HBV-related HCC patient samples[[50](#_ENREF_50)]. A large number of components are involved in each of these pathways, many of which may pose effects on the tumor initiation, promotion and progression, which challenges the screening of potential therapeutic drugs for treatment. Insertional mutagenesis by the *SB* transposon system is a powerful tool for studying HBV-induced HCC through forward genetic screens, and *SB*-mediated gene delivery is a powerful tool for reverse genetic studies. *Snd1,*an oncogene that promotes HCC angiogenesis, was a recurrent CIS gene in liver tumor samples from various studies using the *SB* transposon system forward genetic approach including a study done in the context of transgenic HBsAg expression[[63](#_ENREF_63),[65-67](#_ENREF_65)]. Many other candidate genes likely to play a role in promoting HBV-associated HCC have been identified in these studies. There is also ample data on genes commonly mutated in HBV-associated liver tumors, and genes whose expression or function may be altered by HBV proteins. We have developed a unique rapid *in vivo* model to validate candidate liver cancer genes that can be used to study potential drivers of HBV-associated HCC. It relies on the use of the *Fah*-deficient mouse that is transgenic for the *SB* transposase gene (*Fah-/-*/*SB+/-*)[[81](#_ENREF_81), [84](#_ENREF_84)]. As described earlier, candidate genes can be easily cloned into transposon-based delivery gene vectors and introduced specifically into the livers of these mice using hydrodynamic tail vein injection[[59](#_ENREF_59)]. This system can be used to study both cellular and viral genes. Importantly, these models could be used in pre-clinical trials to test novel therapeutic drugs. Therefore, we propose to use this rapid system to generate many genetic mouse models of HBV-induced HCC to further investigate the tumorigenic mechanisms. Currently, we have generated mouse models that recapitulate several molecular subclasses of human HCC: *neuroblastoma RAS viral (v-ras) oncogene homolog* (*NRAS*), *CTNNB1*, Poly7, and HBV-induced[[37](#_ENREF_37), [65](#_ENREF_65), [81](#_ENREF_81)]. The heterogeneity and complexity of HBV-induced HCC has thus far precluded the full understanding of the genetic mechanisms associated with this deadly disease needed to develop effective treatments and preclinical models. We believe the *SB* transposon system may allow the discovery of drug targets and development of preclinical models desperately needed to advance this field.

**REFERENCES**

1 **Scudellari M**. Drug development: try and try again. *Nature* 2014; **516**: S4-S6 [PMID: 25470198 DOI: 10.1038/516S4a]

2 **Venook AP**, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. *Oncologist* 2010; **15** Suppl 4: 5-13 [PMID: 21115576 DOI: 10.1634/theoncologist.2010-S4-05]

3 **El-Serag HB**. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology* 2012; **142**: 1264-1273.e1 [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061]

4 **Zhang Q**, Cao G. Genotypes, mutations, and viral load of hepatitis B virus and the risk of hepatocellular carcinoma: HBV properties and hepatocarcinogenesis. *Hepat Mon* 2011; **11**: 86-91 [PMID: 22087123]

5 **Cao GW**. Clinical relevance and public health significance of hepatitis B virus genomic variations. *World J Gastroenterol* 2009; **15**: 5761-5769 [PMID: 19998495]

6 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

7 **Li Z**, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. *Cell* 2012; **148**: 72-83 [PMID: 22265403 DOI: 10.1016/j.cell.2011.11.026]

8 **Naugler WE**, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. *Science* 2007; **317**: 121-124 [PMID: 17615358 DOI: 317/5834/121]

9 **Liu WC**, Liu QY. Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. *World J Gastroenterol* 2014; **20**: 6252-6261 [PMID: 24876746 DOI: 10.3748/wjg.v20.i20.6252]

10 **Wu MH**, Ma WL, Hsu CL, Chen YL, Ou JH, Ryan CK, Hung YC, Yeh S, Chang C. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. *Sci Transl Med* 2010; **2**: 32ra35 [PMID: 20484730 DOI: 10.1126/scitranslmed.3001143]

11 **Gerlich WH**. Medical virology of hepatitis B: how it began and where we are now. *Virol J* 2013; **10**: 239 [PMID: 23870415 DOI: 10.1186/1743-422X-10-239]

12 **Di Bisceglie AM**. Hepatitis B and hepatocellular carcinoma. *Hepatology* 2009; **49**: S56-S60 [PMID: 19399807 DOI: 10.1002/hep.22962]

13 **Neuveut C**, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. *J Hepatol* 2010; **52**: 594-604 [PMID: 20185200 DOI: 10.1016/j.jhep.2009.10.033]

14 **Chan HL**, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, Sung JJ. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. *Gut* 2004; **53**: 1494-1498 [PMID: 15361502 DOI: 10.1136/gut.2003.033324]

15 **Ayub A**, Ashfaq UA, Haque A. HBV induced HCC: major risk factors from genetic to molecular level. *Biomed Res Int* 2013; **2013**: 810461 [PMID: 23991421 DOI: 10.1155/2013/810461]

16 **Gong DY**, Chen EQ, Huang FJ, Leng XH, Cheng X, Tang H. Role and functional domain of hepatitis B virus X protein in regulating HBV transcription and replication in vitro and in vivo. *Viruses* 2013; **5**: 1261-1271 [PMID: 23698398 DOI: 10.3390/v5051261]

17 **Ghany M**, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. *Gastroenterology* 2007; **132**: 1574-1585 [PMID: 17408658 DOI: S0016-5085(07)00398-8]

18 **Churin Y**, Roderfeld M, Roeb E. Hepatitis B virus large surface protein: function and fame. *Hepatobiliary Surg Nutr* 2015; **4**: 1-10 [PMID: 25713800 DOI: 10.3978/j.issn.2304-3881.2014.12.08]

19 **Tarocchi M**, Polvani S, Marroncini G, Galli A. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. *World J Gastroenterol* 2014; **20**: 11630-11640 [PMID: 25206269 DOI: 10.3748/wjg.v20.i33.11630]

20 **Yan H**, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. *Elife* 2012; **1**: e00049 [PMID: 23150796 DOI: 10.7554/eLife.00049]

21 **Meier A**, Mehrle S, Weiss TS, Mier W, Urban S. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. *Hepatology* 2013; **58**: 31-42 [PMID: 23213046 DOI: 10.1002/hep.26181]

22 **Yeung P**, Wong DK, Lai CL, Fung J, Seto WK, Yuen MF. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. *J Infect Dis* 2011; **203**: 646-654 [PMID: 21227916 DOI: 10.1093/infdis/jiq096]

23 **Lin CM**, Wang GM, Jow GM, Chen BF. Functional analysis of hepatitis B virus pre-s deletion variants associated with hepatocellular carcinoma. *J Biomed Sci* 2012; **19**: 17 [PMID: 22313590 DOI: 10.1186/1423-0127-19-17]

24 **Na B**, Huang Z, Wang Q, Qi Z, Tian Y, Lu CC, Yu J, Hanes MA, Kakar S, Huang EJ, Ou JH, Liu L, Yen TS. Transgenic expression of entire hepatitis B virus in mice induces hepatocarcinogenesis independent of chronic liver injury. *PLoS One* 2011; **6**: e26240 [PMID: 22022578 DOI: 10.1371/journal.pone.0026240]

25 **Shen T**, Yan XM, Zhang JP, Wang JL, Zuo RX, Li L, Wang LP. Evolution of Hepatitis B Virus in a Chronic HBV-Infected Patient over 2 Years. *Hepat Res Treat* 2011; **2011**: 939148 [PMID: 21785721 DOI: 10.1155/2011/939148]

26 **Datta S**, Chatterjee S, Veer V, Chakravarty R. Molecular biology of the hepatitis B virus for clinicians. *J Clin Exp Hepatol* 2012; **2**: 353-365 [PMID: 25755457 DOI: 10.1016/j.jceh.2012.10.003]

27 **Qu L**, Kuai X, Liu T, Chen T, Ni Z, Shen X. Pre-S deletion and complex mutations of hepatitis B virus related to young age hepatocellular carcinoma in Qidong, China. *PLoS One* 2013; **8**: e59583 [PMID: 23555717 DOI: 10.1371/journal.pone.0059583]

28 **Zhang D**, Dong P, Zhang K, Deng L, Bach C, Chen W, Li F, Protzer U, Ding H, Zeng C. Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment. *BMC Microbiol* 2012; **12**: 307 [PMID: 23272650 DOI: 10.1186/1471-2180-12-307]

29 **Brechot C**, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P, Tiollais P. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms. *Pathol Biol* (Paris) 2010; **58**: 278-287 [PMID: 20667665 DOI: 10.1016/j.patbio.2010.05.001]

30 **Lu JW**, Hsia Y, Tu HC, Hsiao YC, Yang WY, Wang HD, Yuh CH. Liver development and cancer formation in zebrafish. *Birth Defects Res C Embryo Today* 2011; **93**: 157-172 [PMID: 21671355 DOI: 10.1002/bdrc.20205]

31 **Tian Y**, Yang W, Song J, Wu Y, Ni B. Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. *Mol Cell Biol* 2013; **33**: 2810-2816 [PMID: 23716588 DOI: 10.1128/MCB.00205-13]

32 **van de Klundert MA**, van Hemert FJ, Zaaijer HL, Kootstra NA. The hepatitis B virus x protein inhibits thymine DNA glycosylase initiated base excision repair. *PLoS One* 2012; **7**: e48940 [PMID: 23145031 DOI: 10.1371/journal.pone.0048940]

33 **Qadri I**, Fatima K, AbdeL-Hafiz H. Hepatitis B virus X protein impedes the DNA repair via its association with transcription factor, TFIIH. *BMC Microbiol* 2011; **11**: 48 [PMID: 21375739 DOI: 10.1186/1471-2180-11-48]

34 **Matsuda Y**, Ichida T. Impact of hepatitis B virus X protein on the DNA damage response during hepatocarcinogenesis. *Med Mol Morphol* 2009; **42**: 138-142 [PMID: 19784739 DOI: 10.1007/s00795-009-0457-8]

35 **Hsieh YH**, Hsu JL, Su IJ, Huang W. Genomic instability caused by hepatitis B virus: into the hepatoma inferno. *Front Biosci (Landmark Ed)* 2011; **16**: 2586-2597 [PMID: 21622197]

36 **Cha MY**, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. *Hepatology* 2004; **39**: 1683-1693 [PMID: 15185310 DOI: 10.1002/hep.20245]

37 **Keng VW**, Tschida BR, Bell JB, Largaespada DA. Modeling hepatitis B virus X-induced hepatocellular carcinoma in mice with the Sleeping Beauty transposon system. *Hepatology* 2011; **53**: 781-790 [PMID: 21374658 DOI: 10.1002/hep.24091]

38 **Lin X**, Xu X, Huang QL, Liu YQ, Zheng DL, Chen WN, Lin JY. Biological impacts of "hot-spot" mutations of hepatitis B virus X proteins are genotype B and C differentiated. *World J Gastroenterol* 2005; **11**: 4703-4708 [PMID: 16094714]

39 **Lindh M**, Gustavson C, Mårdberg K, Norkrans G, Dhillon AP, Horal P. Mutation of nucleotide 1,762 in the core promoter region during hepatitis B e seroconversion and its relation to liver damage in hepatitis B e antigen carriers. *J Med Virol* 1998; **55**: 185-190 [PMID: 9624604 DOI: 10.1002/(SICI)1096-9071(199807)55]

40 **Lizzano RA**, Yang B, Clippinger AJ, Bouchard MJ. The C-terminal region of the hepatitis B virus X protein is essential for its stability and function. *Virus Res* 2011; **155**: 231-239 [PMID: 20969903 DOI: 10.1016/j.virusres.2010.10.013]

41 **Luo N**, Cai Y, Zhang J, Tang W, Slagle BL, Wu X, He S. The C-terminal region of the hepatitis B virus X protein is required for its stimulation of HBV replication in primary mouse hepatocytes. *Virus Res* 2012; **165**: 170-178 [PMID: 22387566 DOI: 10.1016/j.virusres.2012.02.013]

42 **Ma NF**, Lau SH, Hu L, Xie D, Wu J, Yang J, Wang Y, Wu MC, Fung J, Bai X, Tzang CH, Fu L, Yang M, Su YA, Guan XY. COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. *Clin Cancer Res* 2008; **14**: 5061-5068 [PMID: 18698024 DOI: 10.1158/1078-0432.CCR-07-5082]

43 **Toh ST**, Jin Y, Liu L, Wang J, Babrzadeh F, Gharizadeh B, Ronaghi M, Toh HC, Chow PK, Chung AY, Ooi LL, Lee CG. Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. *Carcinogenesis* 2013; **34**: 787-798 [PMID: 23276797 DOI: 10.1093/carcin/bgs406]

44 **Sze KMF,** Chu GKY, Lee JMF, Ng IOL. C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by c-jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. *Hepatology* 2013; **57**: 131-139 [DOI: 10.1002/Hep.25979]

45 **Kew MC**. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. *J Gastroenterol Hepatol* 2011; **26** Suppl 1: 144-152 [PMID: 21199526 DOI: 10.1111/j.1440-1746.2010.06546.x]

46 **Yip WK**, Cheng AS, Zhu R, Lung RW, Tsang DP, Lau SS, Chen Y, Sung JG, Lai PB, Ng EK, Yu J, Wong N, To KF, Wong VW, Sung JJ, Chan HL. Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development. *PLoS One* 2011; **6**: e22888 [PMID: 21829663 DOI: 10.1371/journal.pone.0022888]

47 **Chemin I**, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. *Cancer Lett* 2009; **286**: 52-59 [PMID: 19147276 DOI: 10.1016/j.canlet.2008.12.003]

48 **Thompson MD**, Wickline ED, Bowen WB, Lu A, Singh S, Misse A, Monga SP. Spontaneous repopulation of β-catenin null livers with β-catenin-positive hepatocytes after chronic murine liver injury. *Hepatology* 2011; **54**: 1333-1343 [PMID: 21721031 DOI: 10.1002/hep.24506]

49 **Totoki Y**, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, Donehower LA, Slagle BL, Nakamura H, Yamamoto S, Shinbrot E, Hama N, Lehmkuhl M, Hosoda F, Arai Y, Walker K, Dahdouli M, Gotoh K, Nagae G, Gingras MC, Muzny DM, Ojima H, Shimada K, Midorikawa Y, Goss JA, Cotton R, Hayashi A, Shibahara J, Ishikawa S, Guiteau J, Tanaka M, Urushidate T, Ohashi S, Okada N, Doddapaneni H, Wang M, Zhu Y, Dinh H, Okusaka T, Kokudo N, Kosuge T, Takayama T, Fukayama M, Gibbs RA, Wheeler DA, Aburatani H, Shibata T. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. *Nat Genet* 2014; **46**: 1267-1273 [PMID: 25362482 DOI: 10.1038/ng.3126]

50 **Schulze K**, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. *Nat Genet* 2015; **47**: 505-511 [PMID: 25822088 DOI: 10.1038/ng.3252]

51 **Amaddeo G**, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Gaston Mathe Y, Laurent C, Laurent A, Bioulac-Sage P, Calderaro J, Zucman-Rossi J. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. *Gut* 2015; **64**: 820-829 [PMID: 25021421 DOI: gutjnl-2013-306228]

52 **Chittmittrapap S**, Chieochansin T, Chaiteerakij R, Treeprasertsuk S, Klaikaew N, Tangkijvanich P, Komolmit P, Poovorawan Y. Prevalence of aflatoxin induced p53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg). *Asian Pac J Cancer Prev* 2013; **14**: 7675-7679 [PMID: 24460352]

53 **Jiang W**, Wang XW, Unger T, Forgues M, Kim JW, Hussain SP, Bowman E, Spillare EA, Lipsky MM, Meck JM, Cavalli LR, Haddad BR, Harris CC. Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. *Int J Cancer* 2010; **127**: 1011-1020 [PMID: 20017137 DOI: 10.1002/ijc.25118]

54 **Kan Z**, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J, Hauptschein R, Rejto PA, Fernandez J, Wang G, Zhang Q, Wang B, Chen R, Wang J, Lee NP, Zhou W, Lin Z, Peng Z, Yi K, Chen S, Li L, Fan X, Yang J, Ye R, Ju J, Wang K, Estrella H, Deng S, Wei P, Qiu M, Wulur IH, Liu J, Ehsani ME, Zhang C, Loboda A, Sung WK, Aggarwal A, Poon RT, Fan ST, Wang J, Hardwick J, Reinhard C, Dai H, Li Y, Luk JM, Mao M. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. *Genome Res* 2013; **23**: 1422-1433 [PMID: 23788652 DOI: 10.1101/gr.154492.113]

55 **Woo HG**, Kim SS, Cho H, Kwon SM, Cho HJ, Ahn SJ, Park ES, Lee JS, Cho SW, Cheong JY. Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma. *PLoS One* 2014; **9**: e115152 [PMID: 25521761 DOI: 10.1371/journal.pone.0115152]

56 **Uren AG,** Kool J, Berns A, van Lohuizen M. Retroviral insertional mutagenesis: past, present and future. *Oncogene* 2005; **24**: 7656-7672 [PMID: 16299527 DOI: 10.1038/sj.onc.1209043]

57 **Ivics Z**, Hackett PB, Plasterk RH, Izsvák Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. *Cell* 1997; **91**: 501-510 [PMID: 9390559]

58 **Dupuy AJ**. Transposon-based screens for cancer gene discovery in mouse models. *Semin Cancer Biol* 2010; **20**: 261-268 [PMID: 20478384 DOI: 10.1016/j.semcancer.2010.05.003]

59 **Bell JB**, Podetz-Pedersen KM, Aronovich EL, Belur LR, McIvor RS, Hackett PB. Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. *Nat Protoc* 2007; **2**: 3153-3165 [PMID: 18079715 DOI: nprot.2007.471]

60 **Keng VW**, Yae K, Hayakawa T, Mizuno S, Uno Y, Yusa K, Kokubu C, Kinoshita T, Akagi K, Jenkins NA, Copeland NG, Horie K, Takeda J. Region-specific saturation germline mutagenesis in mice using the Sleeping Beauty transposon system. *Nat Methods* 2005; **2**: 763-769 [PMID: 16179923 DOI: nmeth795]

61 **Dupuy AJ**, Fritz S, Largaespada DA. Transposition and gene disruption in the male germline of the mouse. *Genesis* 2001; **30**: 82-88 [PMID: 11416868 DOI: 10.1002/gene.1037]

62 **Luo G**, Ivics Z, Izsvák Z, Bradley A. Chromosomal transposition of a Tc1/mariner-like element in mouse embryonic stem cells. *Proc Natl Acad Sci U S A* 1998; **95**: 10769-10773 [PMID: 9724779]

63 **Bard-Chapeau EA**, Nguyen AT, Rust AG, Sayadi A, Lee P, Chua BQ, New LS, de Jong J, Ward JM, Chin CK, Chew V, Toh HC, Abastado JP, Benoukraf T, Soong R, Bard FA, Dupuy AJ, Johnson RL, Radda GK, Chan EC, Wessels LF, Adams DJ, Jenkins NA, Copeland NG. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. *Nat Genet* 2014; **46**: 24-32 [PMID: 24316982 DOI: 10.1038/ng.2847]

64 **Dupuy AJ,** Rogers LM, Kim J, Nannapaneni K, Starr TK, Liu P, Largaespada DA, Scheetz TE, Jenkins NA, Copeland NG. A Modified Sleeping Beauty Transposon System That Can Be Used to Model a Wide Variety of Human Cancers in Mice. *Cancer Res* 2009; **69**: 8150-8156 [PMID: 19808965 DOI: 10.1158/0008-5472.Can-09-1135]

65 **Keng VW**, Sia D, Sarver AL, Tschida BR, Fan D, Alsinet C, Solé M, Lee WL, Kuka TP, Moriarity BS, Villanueva A, Dupuy AJ, Riordan JD, Bell JB, Silverstein KA, Llovet JM, Largaespada DA. Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. *Hepatology* 2013; **57**: 120-130 [PMID: 22899566 DOI: 10.1002/hep.26004]

66 **Keng VW**, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, Matise I, Silverstein KA, Sarver A, Starr TK, Akagi K, Tessarollo L, Collier LS, Powers S, Lowe SW, Jenkins NA, Copeland NG, Llovet JM, Largaespada DA. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. *Nat Biotechnol* 2009; **27**: 264-274 [PMID: 19234449 DOI: nbt.1526]

67 **O'Donnell KA**, Keng VW, York B, Reineke EL, Seo D, Fan D, Silverstein KA, Schrum CT, Xie WR, Mularoni L, Wheelan SJ, Torbenson MS, O'Malley BW, Largaespada DA, Boeke JD. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. *Proc Natl Acad Sci U S A* 2012; **109**: E1377-E1386 [PMID: 22556267 DOI: 1115433109]

68 **Collier LS**, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. *Nature* 2005; **436**: 272-276 [PMID: 16015333 DOI: 10.1038/nature03681]

69 **Starr TK**, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT, Largaespada DA. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. *Science* 2009; **323**: 1747-1750 [PMID: 19251594 DOI: 10.1126/science.1163040]

70 **Moriarity BS**, Otto GM, Rahrmann EP, Rathe SK, Wolf NK, Weg MT, Manlove LA, LaRue RS, Temiz NA, Molyneux SD, Choi K, Holly KJ, Sarver AL, Scott MC, Forster CL, Modiano JF, Khanna C, Hewitt SM, Khokha R, Yang Y, Gorlick R, Dyer MA, Largaespada DA. A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. *Nat Genet* 2015; **47**: 615-624 [PMID: 25961939 DOI: 10.1038/ng.3293]

71 **Rahrmann EP**, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M, Huang W, Largaespada DA, Marker PC. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. *Cancer Res* 2009; **69**: 4388-4397 [PMID: 19401450 DOI: 10.1158/0008-5472.CAN-08-3901]

72 **Rahrmann EP**, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA, Wolf NK, Sarver A, Collins MH, Moertel CL, Wallace MR, Gel B, Serra E, Ratner N, Largaespada DA. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. *Nat Genet* 2013; **45**: 756-766 [PMID: 23685747 DOI: 10.1038/ng.2641]

73 **Mann MB**, Black MA, Jones DJ, Ward JM, Yew CC, Newberg JY, Dupuy AJ, Rust AG, Bosenberg MW, McMahon M, Print CG, Copeland NG, Jenkins NA. Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma. *Nat Genet* 2015; **47**: 486-495 [PMID: 25848750 DOI: 10.1038/ng.3275]

74 **Dupuy AJ**, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. *Nature* 2005; **436**: 221-226 [PMID: 16015321 DOI: 10.1038/nature03691]

75 **Riordan JD**, Keng VW, Tschida BR, Scheetz TE, Bell JB, Podetz-Pedersen KM, Moser CD, Copeland NG, Jenkins NA, Roberts LR, Largaespada DA, Dupuy AJ. Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis. *PLoS Genet* 2013; **9**: e1003441 [PMID: 23593033 DOI: 10.1371/journal.pgen.1003441]

76 **Huo TI**, Wang XW, Forgues M, Wu CG, Spillare EA, Giannini C, Brechot C, Harris CC. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. *Oncogene* 2001; **20**: 3620-3628 [PMID: 11439325 DOI: 10.1038/sj.onc.1204495]

77 **Wang XW**, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. *Proc Natl Acad Sci U S A* 1994; **91**: 2230-2234 [PMID: 8134379]

78 **Wang XW**, Gibson MK, Vermeulen W, Yeh H, Forrester K, Stürzbecher HW, Hoeijmakers JH, Harris CC. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. *Cancer Res* 1995; **55**: 6012-6016 [PMID: 8521383]

79 **Gao J**, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal* 2013; **6**: pl1 [PMID: 23550210 DOI: 10.1126/scisignal.2004088]

80 **Cerami E**, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012; **2**: 401-404 [PMID: 22588877 DOI: 10.1158/2159-8290.CD-12-0095]

81 **Wangensteen KJ**, Wilber A, Keng VW, He Z, Matise I, Wangensteen L, Carson CM, Chen Y, Steer CJ, McIvor RS, Largaespada DA, Wang X, Ekker SC. A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver. *Hepatology* 2008; **47**: 1714-1724 [PMID: 18435462 DOI: 10.1002/hep.22195]

82 **Suda T**, Liu D. Hydrodynamic gene delivery: its principles and applications. *Mol Ther* 2007; **15**: 2063-2069 [PMID: 17912237 DOI: 6300314]

83 **Montini E**, Held PK, Noll M, Morcinek N, Al-Dhalimy M, Finegold M, Yant SR, Kay MA, Grompe M. In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. *Mol Ther* 2002; **6**: 759-769 [PMID: 12498772 DOI: S1525001602908129]

84 **Grompe M**, al-Dhalimy M, Finegold M, Ou CN, Burlingame T, Kennaway NG, Soriano P. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. *Genes Dev* 1993; **7**: 2298-2307 [PMID: 8253378]

85 **Li L**, Shen H, Li A, Zhang Z, Wang B, Wang J, Zheng X, Wu J, Yang D, Lu M, Song J. Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B. *Virol J* 2013; **10**: 214 [PMID: 23805945 DOI: 10.1186/1743-422X-10-214]

86 **Peng XH**, Ren XN, Chen LX, Shi BS, Xu CH, Fang Z, Liu X, Chen JL, Zhang XN, Hu YW, Zhou XH. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice. *World J Gastroenterol* 2015; **21**: 3527-3536 [PMID: 25834317 DOI: 10.3748/wjg.v21.i12.3527]

87 **Wu J**, Huang S, Zhao X, Chen M, Lin Y, Xia Y, Sun C, Yang X, Wang J, Guo Y, Song J, Zhang E, Wang B, Zheng X, Schlaak JF, Lu M, Yang D. Poly(I: C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. *J Virol* 2014; **88**: 10421-10431 [PMID: 24920792 DOI: 10.1128/JVI.00996-14]

**P-Reviewer:** Cao GW, Mizuguchi T **S-Editor:** Qi Y


**L-Editor: E-Editor:**

**Table 1** **Hepatocellular carcinoma Signaling pathways identified by *SB* transposon insertional mutagenesis system[**[**63**](#_ENREF_63)**,** [**66**](#_ENREF_66)**].**


|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Pathways** | **Wnt/Ctnnb1** | **Trp53** | **Pi3k-Akt-Mtor** | **Mapk** | **Hippo** | **Tgfb-Bmp** | **Il6-Stat3** | **Tnf-Akt1** |
| Genes involved in corresponding pathways | *Lrp1* | *Prkag2* | *Insr* | *Egfr* | *Fat1* | *Acvr1* | *Il6st (gp130)* | *Tnf* |
| *Lrp5* | *Ywhaz* | *Igf1* | *Met* | *Wwc1* | *Acvr2a* | *Jak1* | *Egfr* |
| *Lrp6* | *Crebbp* | *Pten* | *Grb2* | *Taok1* | *Bmp1* | *Stat3* | *Met* |
| *Gsk3b* | *Mdm2* | *Pik3ca* | *Sos1* | *Taok2* | *Bmpr1a* |  | *Pak4* |
| *Axin1* | *Usp10* | *Pik3r1* | *Sos2* | *Taok3* | *Sar1a* |  | *Nfib* |
| *Apc* | *Usp7* | *Pik3c2a* | *Kras* | *Mobkl2b* | *Tab2* |  | *Taok3* |
| *Ctnnb1* | *Pias1* | *Pik3ap1* | *Raf1* | *Mobkl1a* | *Tab3* |  | *Map2k4* |
| *Tcf7l2* | *trp53inp1* | *Akt2* | *Map3k1* | *Sav1* | *Smad3* |  | *Akt* |
| *Csnk1a1* | *Ppp2r1a* | *Rps6kb1* | *Map3k2* | *Lats1* | *Smad2* |  | *Hif1a* |
| *Csnk1d* | *Ppp2r2a* | *Foxo1* | *Map2k1* | *Yap1* | *Smad1* |  | *Ube2h* |
| *Csnk1g1* | *Ppp2r2d* |  | *Mapk1* | *Tead1* | *Smad4* |  | *Qk* |
| *Csnk1g3* | *Ppp2cb* |  |  |  | *Smad5* |  | *Pi3k* |
| *Tnks* | *Ppp2r5e* |  |  |  |  |  | *Jnk* |
| *Tnks2* | *Trp53* |  |  |  |  |  |  |

1Indicates a network.


**Figure 1** **Structure of the hepatitis B virus genome.** Hepatitis B virus (HBV) consists of an incomplete double stranded DNA with four open reading frames: surface proteins coding gene (PreS1/S2/S), polymerase encoding gene (POL), X protein encoding gene (X), and core protein encoding gene (PreC/C)[[17](#_ENREF_17)].




**Figure 2** **Diagrammatical presentation of the PreS1/S2 deletion mutants.** (Top) 3’-end PreS1 deletion mutant and (Bottom) 5’-end PreS2 deletion mutant are two common mutation forms found in HBV-induced HCC patients. Both mutants produce truncated large surface proteins (L’ and L”). M, middle protein; S, small protein. HBs gene nucleotide position 2848 to 835 as shown in Figure 1.




**Figure 3 Common mutations in the *HBx* gene.** Substitution mutation at nucleotide positions T1753C, A1762T, G1764A and T1768A; and C-terminal truncation ranging from nucleotide position 1647 to 1790 observed in human HCC tumor samples[[43](#_ENREF_43)]. HBx gene nucleotide position 1374 to 1834 as shown in Figure 1.




**Figure 4** **Life cycle of the hepatitis B virus.** HBV enters the hepatocyte and is uncoated in the cytoplasm. The relaxed-circular viral DNA (RC-DNA) is released from the nucleocapsid into the host nucleus and is converted into covalently closed circular DNA (cccDNA). The cccDNA acts as a template for transcription of pregenomic virion RNAs (Pg-RNA). Pg-RNA is then transferred into the cytoplasm, bound by viral polymerase and encapsidated. Inside the nucleocapsid, the Pg-RNA is reverse transcribed into RC-DNA, where either the RC-DNA can be released back into the host nucleus for amplification of viral DNA or the entire nucleocapsid can be transferred into the endoplasmic reticulum (ER) for viral surface protein coating and ultimately released from the cell[[13](#_ENREF_13)]. S, small surface protein; M, middle surface protein; L, large surface protein.



**Figure 5** **Word cloud of frequent *CIS* genes from three separate studies using *SB* transposon forward genetic screen with different genetic backgrounds[**[**63**](#_ENREF_63)**,**[**65**](#_ENREF_65)**,**[**67**](#_ENREF_67)**].** The roles of these frequent *CIS* gene human orthologs were analyzed using TCGA database. The font size indicates the frequency of genetic alteration reported in human HCC samples. Color of the font indicates the copy number change or expression profile of the gene: red, amplification; blue, deletion; tomato, tends to upregulation; purple, tends to downregulation; yellow, frequently found in all three studies.



**Figure 6 Reverse genetic screening of individual *HBV* gene components using the *Fah-/-*/*SB+/-* transgenic mouse model.** A: Construction of gene delivery expression vectors that carry various individual HBV gene-of-interest (*GOI*) components by PCR amplification and insertion of *GOI* into an entry clone (pENTR) and followed by LR clonase reaction (Life Technologies); B: Hydrodynamic tail vein injection of gene delivery expression vector into *Fah-/-*/*SB+/-* transgenic mouse; C: Liver tumors indicated by white arrowheads observed in *Fah-/-*/*SB+/-* mouse injected with a HBV gene component (left) after 160-days post-hydrodynamic injection. *Fah-/-*/*SB+/-* transgenic mouse injected with an empty gene delivery expression vector displayed normal liver morphology (right). *EGFP*, *enhanced green fluorescent protein gene*; *Luc*, *luciferase* gene; IR/DR, inverted repeat/direct repeat sequences for *Sleeping Beauty* transposase binding and mobilization; pA, polyadenalytion signal; IRES, internal ribosome entry site; *PGK*, *phosphoglycerate kinase 1* promoter; *CAG*, *cytomegalovirus (CMV) enhancer fused to the chicken ß-actin promoter*; attL/R/B sites, recombination sites used by the Gateway cloning system (Life Technologies); *ccdB*, topoisomerase poison from *Escherichia coli*; scale bar, 0.5 cm.

****